Pediatrix Medical Group, Inc. (MD) Q3 2025 Earnings Call Transcript
Pediatrix Medical Group, Inc. ( MD ) Q3 2025 Earnings Call November 3, 2025 9:00 AM EST Company Participants Mary Ann Moore - Chief Administrative Officer, Executive VP, General Counsel & Secretary Mark Ordan - CEO & Executive Chairman Kasandra Rossi - Executive VP, Treasurer & CFO Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Kieran Ryan - Deutsche Bank AG, Research Division Jack Slevin - Jefferies LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Hello. My name is Dustin, and I will be your conference operator today.
Pediatrix Medical's Q3 Test: Can Lower Expenses Drive Earnings?
MD's Q3 earnings may hinge on whether sharp expense cuts can offset declining revenues and sustain its profit momentum.
Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
4 Stocks Trading Near 52-Week High With Room to Rise Further
Investors target stocks that have been on a bullish run. Stocks like MMS, MD, SBH and STT are seeing price strength, and the momentum is likely to continue.
Pediatrix Medical Group, Inc. (MD) Soars to 52-Week High, Time to Cash Out?
Pediatrix Medical Group (MD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Despite Fast-paced Momentum, Pediatrix Medical Group (MD) Is Still a Bargain Stock
Pediatrix Medical Group (MD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Pediatrix Medical Refills Its Buyback Prescription With $250M Dose
MD launches a $250M buyback, fueled by stronger cash flow, leaner operations and robust 2025 profit outlook.
Pediatrix Medical Group (MD) Is Up 11.93% in One Week: What You Should Know
Does Pediatrix Medical Group (MD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pediatrix Medical Group (MD) Is Attractively Priced Despite Fast-paced Momentum
Pediatrix Medical Group (MD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
MD's Q2 earnings benefit from higher patient volumes and a declining expense level. It now projects 2025 adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
Pediatrix Medical Group, Inc. (MD) Q2 2025 Earnings Call Transcript
Pediatrix Medical Group, Inc. (NYSE:MD ) Q2 2025 Earnings Conference Call August 5, 2025 9:00 AM ET Company Participants Kasandra H. Rossi - Executive VP, Treasurer & CFO Mark S.
